Clinical Trial

Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors

Unknown Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 15, 2024 (before its estimated May 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of Anti-CDH17 CAR-T cell injection in patients with CDH17-positive advanced malignant solid tumors.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06501183
Lead Sponsor Shanghai Pudong Hospital
Collaborators: UTC Therapeutics Inc.
Conditions CDH17-positive Advanced Malignant Solid Tumors
Enrollment 17 participants
Start Date 2024-07-08
Primary Completion 2025-05-30 (estimated)
Study Completion 2026-05-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-15